208 related articles for article (PubMed ID: 31350955)
1. The Role of Human Epidermal Growth Factor Receptor (HER2/neu) in the Prognosis of Patients with Gastric Cancer.
Aznab M; Maleksabet D; Khazaei S; Khazaei M; Rezaei M
Asian Pac J Cancer Prev; 2019 Jul; 20(7):1989-1994. PubMed ID: 31350955
[TBL] [Abstract][Full Text] [Related]
2. Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.
Shah MA; Kang YK; Thuss-Patience PC; Ohtsu A; Ajani JA; Van Cutsem E; Hoersch S; Harle-Yge ML; de Haas SL
Gastric Cancer; 2019 Jul; 22(4):803-816. PubMed ID: 30706247
[TBL] [Abstract][Full Text] [Related]
3. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3).
Seo S; Ryu MH; Park YS; Ahn JY; Park Y; Park SR; Ryoo BY; Lee GH; Jung HY; Kang YK
Gastric Cancer; 2019 May; 22(3):527-535. PubMed ID: 30386954
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
5. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
Cho JH; Lim JY; Cho JY
World J Gastroenterol; 2017 Nov; 23(41):7407-7414. PubMed ID: 29151694
[TBL] [Abstract][Full Text] [Related]
6. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of assessing Her2/neu expression in gastric cancer with dual tumor tissue paraffin blocks.
Ge X; Wang H; Zeng H; Jin X; Sujie A; Xu C; Liu Y; Huang J; Ji Y; Tan Y; Liu T; Hou Y; Qin J; Sun Y; Qin X
Hum Pathol; 2015 Jun; 46(6):850-7. PubMed ID: 25863425
[TBL] [Abstract][Full Text] [Related]
8. Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.
Palacio S; Loaiza-Bonilla A; Kittaneh M; Kyriakopoulos C; Ochoa RE; Escobar M; Arango B; Restrepo MH; Merchan JR; Rocha Lima CM; Hosein PJ
Anticancer Res; 2014 Jan; 34(1):301-6. PubMed ID: 24403478
[TBL] [Abstract][Full Text] [Related]
9. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature.
Lei YY; Huang JY; Zhao QR; Jiang N; Xu HM; Wang ZN; Li HQ; Zhang SB; Sun Z
World J Surg Oncol; 2017 Mar; 15(1):68. PubMed ID: 28327158
[TBL] [Abstract][Full Text] [Related]
10. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of HER-2/neu overexpression in gastric carcinoma using a tissue microarray.
Rakhshani N; Kalantari E; Bakhti H; Sohrabi MR; Mehrazma M
Asian Pac J Cancer Prev; 2014; 15(18):7597-602. PubMed ID: 25292034
[TBL] [Abstract][Full Text] [Related]
12. [Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma].
Song Y; Huang J; Wang JW
Chin J Cancer; 2010 Jan; 29(1):76-81. PubMed ID: 20038314
[TBL] [Abstract][Full Text] [Related]
13. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation.
Qiu MZ; Li Q; Wang ZQ; Liu TS; Liu Q; Wei XL; Jin Y; Wang DS; Ren C; Bai L; Zhang DS; Wang FH; Li YH; Xu RH
Int J Cancer; 2014 May; 134(10):2468-77. PubMed ID: 24155030
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer.
Matsushita D; Uenosono Y; Arigami T; Yanagita S; Okubo K; Kijima T; Miyazono F; Hamanoue M; Hokita S; Nakashima S; Ohtsuka T; Natsugoe S
Cancer Chemother Pharmacol; 2021 Jun; 87(6):789-797. PubMed ID: 33641065
[TBL] [Abstract][Full Text] [Related]
15. HER2 EXPRESSION AS A PROGNOSTIC FACTOR IN METASTATIC GASTRIC CANCER.
Junior PN; Neto RA; Forones NM
Arq Gastroenterol; 2016; 53(2):62-7. PubMed ID: 27305410
[TBL] [Abstract][Full Text] [Related]
16. [Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
Shen L; Xu JM; Feng FY; Jiao SC; Wang LW; Li J; Guan ZZ; Qin SK; Wang JJ; Yu SY; Wang YJ; Jin YN; Tao M; Zheng LZ; Pan LX
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):295-300. PubMed ID: 23985260
[TBL] [Abstract][Full Text] [Related]
17. Impact of HER2 expression on outcome in gastric cancer patients with liver metastasis.
Jiang H; Li Q; Yu S; Yu Y; Wang Y; Li W; Cui Y; Liu T
Clin Transl Oncol; 2017 Feb; 19(2):197-203. PubMed ID: 27324991
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of Human epidermal growth factor receptor-2 expression in patients with resectable gastric adenocarcinoma.
Kim H; Seo S; Kim K; Park YH; An M; Baik H; Choi C; Oh S
World J Surg Oncol; 2019 Jul; 17(1):122. PubMed ID: 31296222
[TBL] [Abstract][Full Text] [Related]
20. Relation between transforming growth factor-β1 expression, its receptor and clinicopathological factors and survival in HER2-negative gastric cancers.
Ananiev J; Gulubova M; Tchernev G; Penkova M; Miteva R; Julianov A; Manolova I
Wien Klin Wochenschr; 2011 Nov; 123(21-22):668-73. PubMed ID: 22015652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
